Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety

Casey W. Williamson, Michael V. Sherer, Dmitriy Zamarin, Andrew B. Sharabi, Brandon A. Dyer, Loren K. Mell, Jyoti S. Mayadev

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations

Abstract

Radiation therapy exerts a tumoricidal local effect as well as both local and systemic immunomodulation. Immune checkpoint blockade has become a widely used treatment modality across cancer types with a rapidly growing list of agents and US Food and Drug Administration-approved indications. Moreover, there may be synergy between radiation therapy and immune checkpoint blockade. Various strategies have been used, but the optimal sequencing of these therapies is unclear. In this review, the authors discuss the major mechanisms of available immune checkpoint inhibitors and explore the available preclinical and clinical evidence regarding treatment sequencing. They also review safety considerations and conclude with possible future directions.

Original languageEnglish (US)
Pages (from-to)1553-1567
Number of pages15
JournalCancer
Volume127
Issue number10
DOIs
StatePublished - May 15 2021
Externally publishedYes

Keywords

  • cancer therapy sequencing
  • immune checkpoint blockade
  • immunotherapy
  • radiation therapy
  • radiosensitization

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety'. Together they form a unique fingerprint.

Cite this